Equities

Biodesix Inc

BDSX:NMQ

Biodesix Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.37
  • Today's Change0.04 / 3.01%
  • Shares traded1.34k
  • 1 Year change+3.01%
  • Beta1.1371
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

  • Revenue in USD (TTM)65.56m
  • Net income in USD-43.82m
  • Incorporated2005
  • Employees217.00
  • Location
    Biodesix Inc919 West Dillon RoadLOUISVILLE 80027United StatesUSA
  • Phone+1 (303) 417-0500
  • Fax+1 (303) 417-9700
  • Websitehttps://www.biodesix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cardiff Lexington Corp10.50m1.17m105.26m10.000.6132--88.2410.0211.426.772.440.76780.5159--0.87481,050,259.009.67-18.6725.68--69.3862.0118.74-23.33--2.950.4169--10.8539.71164.24------
23andMe Holding Co.199.19m-631.48m107.96m560.00--15.80--0.542-1.31-1.310.41120.28360.32158.2876.27355,692.80-101.91---130.54--44.7946.35-317.03-121.631.43--0.00---26.66-13.01-113.92---19.09--
Zomedica Corp26.08m-55.99m117.59m144.00--0.5634--4.51-0.0571-0.05710.02660.2130.10541.7912.84181,090.30-22.64-14.03-23.35-14.4568.70---214.70-220.9810.68--0.00--33.05---102.93--89.85--
American Oncology Network Inc1.46bn-16.08m123.48m1.53k------0.0846-1.95-1.9591.571.873.5228.8310.64956,595.40-19.18---39.16--4.99---5.45--1.09-10.850.6438--11.27----------
American Well Corp254.04m-214.08m134.66m1.10k--0.3991--0.5301-14.54-14.5417.2222.020.454526.313.74230,104.20-38.46-28.25-49.63-32.6634.8040.51-84.63-121.272.88--0.00---6.5517.85-149.66--51.49--
Longduoduo Co Ltd7.39m1.26m156.96m49.00125.03223.43107.1221.240.04180.04180.24630.02344.17422.8061.99150,812.9076.89--1,467.79--97.65--18.45--1.31--0.00--93.52--3,311.69------
Nutex Health Inc275.93m-37.89m171.59m800.00--2.51--0.6219-8.45-8.4558.9112.580.642785.574.71344,910.60-6.93-69.35-8.57-84.8519.2110.97-10.79-102.851.550.93750.7683--12.93428.2289.22------
Joint Corp120.07m-14.41m174.11m444.00--7.49--1.45-0.9743-0.97438.071.551.32--33.77270,430.40-15.864.32-23.506.0590.8290.28-12.003.68--1,156.170.0022--16.2426.27-1,656.09--35.09--
Biodesix Inc65.56m-43.82m199.29m217.00--7.15--3.04-0.3941-0.39410.56630.19150.6918--9.49302,129.00-46.24-55.60-60.89-80.9477.7259.53-66.84-105.15---3.910.5647--28.4619.1620.32--106.31--
ModivCare Inc2.77bn-160.74m221.43m21.20k--23.30--0.0799-11.31-11.31195.280.66751.60--7.57130,778.60-9.06-1.36-13.29-1.8315.7317.58-5.66-0.9619--0.39780.9919--9.8514.71-542.83--19.27--
Accolade Inc441.03m-80.10m286.71m2.40k--0.6763--0.6501-1.03-1.035.695.260.5477--17.46183,761.70-9.95-24.80-11.44-29.0448.2445.56-18.16-56.43----0.3308--14.0934.3078.29--31.97--
Data as of Nov 08 2024. Currency figures normalised to Biodesix Inc's reporting currency: US Dollar USD

Institutional shareholders

28.54%Per cent of shares held by top holders
HolderShares% Held
Telemark Asset Management LLCas of 30 Jun 20248.28m5.71%
Soleus Capital Management LP (Investment Management)as of 30 Jun 20246.11m4.21%
AIGH Capital Management LLCas of 30 Jun 20245.78m3.98%
Sio Capital Management LLCas of 30 Jun 20244.35m3.00%
Opaleye Management, Inc.as of 30 Jun 20244.02m2.77%
Monashee Investment Management LLCas of 30 Jun 20243.26m2.25%
The Vanguard Group, Inc.as of 30 Jun 20242.89m1.99%
Birchview Capital LPas of 05 Nov 20242.70m1.86%
Perceptive Advisors LLCas of 30 Jun 20242.17m1.50%
Farallon Capital Management LLCas of 30 Jun 20241.88m1.29%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.